Immune regulation by platelet-activating factor: II. Mediation of suppression by cytokine-stimulated endothelial cells in vitro
- PMID: 1997631
- DOI: 10.1002/jlb.49.3.245
Immune regulation by platelet-activating factor: II. Mediation of suppression by cytokine-stimulated endothelial cells in vitro
Abstract
Human umbilical vein endothelial cells (EC) can respond to endotoxin or to the inflammatory cytokines tumor necrosis factor (TNF) and interleukin 1 (IL-1) by producing platelet-activating factor (PAF). When EC were preexposed to TNF-alpha (25 U/ml) for 1 h, and then washed, their subsequent coculture with peripheral blood mononuclear cells (PBMC) resulted in suppressed proliferative response of the latter to the mitogen Con A (P less than 0.05). This effect was completely reversed by the concomitant use of the PAF receptor antagonist BN 52021 (0.1 mM). Preexposure of EC to IL-1 beta (0.5 U/ml) induced similar effects, but IL-1 and TNF were not additive. Removal of monocytes from the PBMC population abolished the effects. On the other hand, coculture of monocytes with cytokine-preexposed EC resulted in significant induction of suppressor activity on lymphocyte proliferation. Our data indicate that EC, preexposed to inflammatory cytokines, can modulate lymphocyte functions via the production of PAF and its action on monocytes.
Similar articles
-
Platelet-activating factor (PAF-acether) enhances the concomitant production of tumour necrosis factor-alpha and interleukin-1 by subsets of human monocytes.Immunology. 1991 Feb;72(2):181-7. Immunology. 1991. PMID: 2016118 Free PMC article.
-
Cytokine-induced monocyte adhesion to endothelial cells involves platelet-activating factor: suppression by conjugated linoleic acid.Biochim Biophys Acta. 2006 Jul;1761(7):793-801. doi: 10.1016/j.bbalip.2006.05.014. Epub 2006 Jun 2. Biochim Biophys Acta. 2006. PMID: 16829183
-
Involvement of a serine protease in the synthesis of platelet-activating factor by endothelial cells stimulated by tumor necrosis factor-alpha or interleukin-1 alpha.Eur J Immunol. 1994 Dec;24(12):3131-9. doi: 10.1002/eji.1830241233. Eur J Immunol. 1994. PMID: 7805742
-
Role of cytokines and platelet-activating factor in microvascular immune injury.Int Arch Allergy Appl Immunol. 1989;88(1-2):88-100. doi: 10.1159/000234755. Int Arch Allergy Appl Immunol. 1989. PMID: 2651321 Review.
-
PAF, cytokines, toxic oxygen products and cell injury.Mol Aspects Med. 1991;12(2):169-74. doi: 10.1016/0098-2997(91)90012-b. Mol Aspects Med. 1991. PMID: 2072825 Review. No abstract available.
Cited by
-
Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis.J Clin Invest. 1995 Aug;96(2):940-52. doi: 10.1172/JCI118142. J Clin Invest. 1995. PMID: 7543496 Free PMC article.
-
Platelet-activating factor stimulates interleukin-6 production by human endothelial cells and synergizes with tumor necrosis factor for enhanced production of granulocyte-macrophage colony stimulating factor.Inflammation. 1997 Apr;21(2):145-58. doi: 10.1023/a:1027314103063. Inflammation. 1997. PMID: 9187959
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources